Adrienne L. Graves - Jul 10, 2023 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role: Director
Signature: /s/Donald Notman, Attorney-in-Fact for Adrienne L. Graves
Stock symbol: OCUL
Transactions as of: Jul 10, 2023
Transactions value $: $0
Form type: 4
Date filed: 7/12/2023, 05:18 PM
Previous filing: May 19, 2023
Next filing: Jul 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUL	Common Stock	Award	$0	+24K		$0.00	24K	Jul 10, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCUL	Stock Option (Right to Buy)	Award	$0	+72K		$0.00	72K	Jul 10, 2023	Common Stock	72K	$5.04	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 10, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant.
F2	Subject to the reporting person's continued service on the Company's board of directors, the options will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant.

Content

On July 10, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant.

Subject to the reporting person's continued service on the Company's board of directors, the options will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant.